GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (FRA:8N1) » Definitions » Notes Receivable

Biosergen AB (FRA:8N1) Notes Receivable : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biosergen AB Notes Receivable?

Biosergen AB's Notes Receivable for the quarter that ended in Dec. 2024 was €0.00 Mil.


Biosergen AB Notes Receivable Historical Data

The historical data trend for Biosergen AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosergen AB Notes Receivable Chart

Biosergen AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
- - - - -

Biosergen AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biosergen AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Biosergen AB Notes Receivable Related Terms

Thank you for viewing the detailed overview of Biosergen AB's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosergen AB Business Description

Traded in Other Exchanges
Address
Fogdevreten 2, Solna, SWE, 17165
Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway, and several other places worldwide. The company is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.

Biosergen AB Headlines

No Headlines